Trial to Evaluate Fecobionics in Fecal Incontinence (FI) (NORMAL and ABNORMAL-FI)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

ClinicalTrials.gov Identifier: NCT05412069

Recruitment Status : Not yet recruiting

First Posted : June 9, 2022

Last Update Posted : July 19, 2022

See Contacts and Locations

Sponsor:

Collaborator:

Augusta University Medical Center

Information provided by (Responsible Party):

Hans Gregersen, PhD, The California Medical Innovations Institute, Inc.

Study Description

Brief Summary:

The objective is to determine the length-tension properties of the anal sphincters using Fecobionics in normal subjects and FI patients during anal distension and during simulated evacuation. Fecobionics has the consistency and shape of normal stool and can record pressures, cross-sectional area, orientation and viscoelastic properties of the anorectum and can map the geometric profiles during evacuation, and thereby provides multi-dimensional measurements of pressures, deformability, and topographic changes. Fecobionics combines several existing tests to provide novel insight into anorectal function. The purpose for the development was to overcome the technological controversies and disagreement between various tests and unphysiological test conditions. The aim was to imitate defecation as much as possible to the natural process. Fecobionics was developed to simulate stool and to provide the driving pressure and resulting deformations of stool along with a measure of an objective anorectal angle during defecation in a single examination. Fecobionics makes it possible to describe objectively, without disturbing the defecation process, the opening characteristics and pressure signatures during initial entry into the relaxing anal canal.

The overall goal is to provide mechanistic understanding of defecation in health and defecatory disorders. It exceeds previous attempts to make artificial stool for evaluation of defecation (BET and FECOM) and integrates other technologies as well. It was designed to have a consistency and deformability of Type 4 (range type 3-5) on the Bristol stool form scale. The range from types 3-5 is found in 70% of normal subjects. A major novelty is that Fecobionics measures pressures in axial direction; i.e., in the flow direction.

Condition or disease	Intervention/treatment	Phase
Normal Subjects Fecal Incontinence	Device: Fecobionics	Not Applicable

Show detailed description

Detailed Description:

Defecatory disorders affect 25% of the population and the incidence is rising. These diseases pose a major health care burden and are poorly recognized and treated. The need for better diagnostics and therapeutics is substantial. Defecatory disorders including constipation and fecal incontinence are associated with diet, aging and a variety of underlying factors and diseases.

Current diagnostic tests such as the balloon expulsion test (BET), high-resolution anorectal manometry (HRM), defecography, and dynamic pelvic MRI are indirect surrogates for the act of defecation, and provide incomplete and often conflicting information, because most of them are not simulating defecation. Most tests are done with the subjects in lateral lying position, which is an abnormal posture for defecation. The results of these tests correlate poorly with symptoms and treatment outcomes. The simplest anorectal physiology test is the BET where a rectal balloon is filled with 50 ml water where expulsion within 1-2 min is considered normal. Anorectal manometry records the pressure exerted by the anal sphincters and puborectalis during rest and contraction. Defecography shows how well the rectum holds and evacuates the stool. Defecography uses a liquid with mechanical properties that are quite dissimilar to feces and hence cannot represent the physiology of defecation. Current research paradigms for defecatory disorders need a new technology that can provide real time, quantitative, and mechanistic insights by simulating defecation physiologically through multi-dimensional measurements of the pressure profiles, deformability, and topographic changes. The investigators have developed a wired Fecobionics device that integrates current tests to provide detailed mapping of physiological parameters during defecation of the device. This device has been further developed to a wireless device with expanded measurements. This was tested in the NORMAL study.

In this study, the investigators would like to learn more about FI patients and obtain ultrasonography data from 15 normal subjects for comparison. Fecal incontinence is a common problem, often nor properly diagnosed and treated. The goals are to determine the role of anorectal muscles in maintaining continence and defecation, and how their malfunction(s) can cause FI by using the new technology (i.e., Fecobionics) and novel methodology. Specifically, the investigators wish to determine the anal length-tension properties, a measure of the active and passive properties of the anal sphincter muscles, i.e. the compliance or stiffness.

Fecal incontinence (FI) affects 1 in 7 Americans with a rising incidence that poses a major healthcare burden. FI pathophysiology is poorly understood and consequently there is a dearth of effective treatment(s) compared to other defecatory disorders including constipation. A critical barrier to progress has been the lack of comprehensive, physiologically relevant and practical diagnostic test for identifying underlying mechanism(s). Current tests provide either incomplete or conflicting information that do not correlate with symptoms and treatment outcomes. The objective is to determine the role of anorectal muscles in maintaining continence and facilitating defecation, and how their malfunction(s) can cause FI by using a novel technology called Fecobionics (an electronic simulated stool) to evaluate the diagnostic and therapeutic utility of the novel technology. Fecobionics has the consistency and shape of normal stool and can record pressures, cross-sectional area, orientation and viscoelastic properties of the anorectum and can map the geometric profiles during evacuation, and thereby provides multi-dimensional measurements of pressures, deformability, and topographic changes. The central hypothesis is that the movement of the Fecobionics device through the anorectum will provide unknown and new mechanistic insights on anorectal physiology including length-tension properties of anorectal muscles, intraluminal pressure changes, deformability, and resistance generated during its movement and distensibility of the anal sphincters in NS and FI patients. Fecobionics studies have been done on more than 100 normal subjects and patients with anorectal disorders in Hong Kong using a structurally similar but simplified wired device that merely measured pressures. The published Fecobionics studies revealed clear differences between normal subjects and FI patients, as well as they demonstrated that the correlation with symptoms are higher with Fecobionics than with current technology (HRM-BET) and the outcome of biofeedback therapy can be predicted with Fecobionics. In this study, the Fecobionics upgraded hardware, software and graphical user interface (GUI) will be used to generate clinical data in FI patients and in later stages it will be used to guide biofeedback training (BT) in FI patients. Whether specific muscle length-tension properties, i.e., the relationship between muscle length and the force the anorectal muscle produces at that length, play a role in the evacuation and continence mechanics in NS and FI patients has not been studied in detail, and until now an appropriate method and system for such an analysis has not been available. The approach is based on promising data using 1) Anal EndoFLIP, 2) the previous wired Fecobionics prototype device (both invented by the PI) and 3) 3D ultrasound with vaginal distension for determining puborectalis length-tension properties, all of which have suggested that these properties are important. The overall objective is to validate a fully integrative dynamic investigational tool that mimics a normal stool for diagnostics and FI treatment. The expected outcomes are that the device will provide new mechanistic insights on anorectal physiology including the contributions of muscle length-tension properties, and facilitate development of new FI treatment strategies including improvement of BT.

Study Design

Layout table for study information

Study Type :	Interventional (Clinical Trial)
Estimated Enrollment :	30 participants
Allocation:	N/A
Intervention Model:	Single Group Assignment
Masking:	None (Open Label)
Primary Purpose:	Basic Science
Official Title:	A Multicenter, Prospective, Non-randomized Study on Pathophysiology, Diagnosis, and Biofeedback Therapy in Fecal Incontinence (FI) Using Fecobionics (NORMAL and ABNORMAL-FI)
Estimated Study Start Date :	August 1, 2022
Estimated Primary Completion Date :	July 31, 2023
Estimated Study Completion Date :	August 1, 2023

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Bowel Movement

U.S. FDA Resources

Arms and Interventions

Arm	Intervention/treatment
Experimental: Fecobionics study Fecobionics	Device: Fecobionics Fecobionics is a novel device to be inserted through the anal canal into rectum for studying defecation. Anorectal manometry, balloon expulsion test, and anal ultrasonography will be used as reference. Other Names: anorectal manometry balloon expulsion test anal ultrasonography

Outcome Measures

Primary Outcome Measures :

Length-tension properties of the anal sphincter will be reported [ Time Frame: 1 year ]
Front-rear pressure difference (in cmH2O) will be measured [ Time Frame: 1 year ]
Fecobionics contain pressure sensors in front end and rear end which can measure pressures

Secondary Outcome Measures :

Anorectal angle (in degree) will be measured [ Time Frame: 1 year ]
Fecobionics contain motion processing units with gyroscopes and accelerometers, which can measure angles
Expulsion velocity (in mm/s) will be reported [ Time Frame: 1 year ]

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information

Ages Eligible for Study:	18 Years to 75 Years (Adult, Older Adult)
Sexes Eligible for Study:	All
Accepts Healthy Volunteers:	Yes

Criteria

Inclusion Criteria:

Subject must provide written informed consent;
Willing and able to undergo required study tests, surveys, and procedures;
Age > 18 and < 75 years of age.

Exclusion Criteria:

Female who is pregnant;
Prior anorectal surgery;
Prior bowel resection;
History of chronic constipation;
In the opinion of the investigator, the subject is not a suitable candidate for the study.

Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05412069

Contacts

Layout table for location contacts

Contact: Hans Gregersen, MD, PhD	8582497400	hag@giome.org
Contact: Satish Rao, MD, PhD	7067212238	srao@augusta.edu

Locations

Layout table for location information

United States, California
California Medical Innovations Institute
San Diego, California, United States, 92121
Contact: Hans Gregersen, PhD 858-249-7400 hag@giome.org
Contact: Ghassan Kassab, PhD 8582497400 gkassab@calmi2.org
Sub-Investigator: Yanmin Wang, MD, PhD
United States, Georgia
Augusta University Medical Center
Augusta, Georgia, United States, 30912
Contact: Satish Rao, MD, PhD 706-721-2238 srao@augusta.edu
Contact: Tennekoon Karunaratne, MD, PhD 7067211968 tkarunaratne@augusta.edu

Sponsors and Collaborators

The California Medical Innovations Institute, Inc.

Augusta University Medical Center

Investigators

Layout table for investigator information

Principal Investigator:	Hans Gregersen, MD, PhD	California Medical Innovations Institute

More Information

Layout table for additonal information

Responsible Party:	Hans Gregersen, PhD, Research Professor, The California Medical Innovations Institute, Inc.
ClinicalTrials.gov Identifier:	NCT05412069
Other Study ID Numbers:	CALM-CLIN-2022 new
First Posted:	June 9, 2022 Key Record Dates
Last Update Posted:	July 19, 2022
Last Verified:	July 2022

Layout table for additional information

Studies a U.S. FDA-regulated Drug Product:	No
Studies a U.S. FDA-regulated Device Product:	No

Keywords provided by Hans Gregersen, PhD, The California Medical Innovations Institute, Inc.:


anorectal Fecobionics defecation

Additional relevant MeSH terms:

Layout table for MeSH terms

Fecal Incontinence Rectal Diseases Intestinal Diseases Gastrointestinal Diseases Digestive System Diseases

To Top